Optimal duration of chemotherapy in small cell lung cancer: A randomized study of 4 versus 6 cycles of cisplatin-etoposide

Journal of Chemotherapy

Volumn 10, Issue 2, 1998, Pages 136-140

  Veslemes, M ^a   Polyzos, A ^a   Latsi, P ^a   Dimitroulis, J ^a   Stamatiadis, D ^a   Dardoufas, C ^b   Rasidakis, A ^a   Katsilambros, N ^a   Jordanoglou, J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Duration of treatment; Etoposide cisplatin; Lung cancer; Small cell lung cancer

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GLUCOSE; MANNITOL; ONDANSETRON; SODIUM CHLORIDE;

ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 0031953380     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.2.136     Document Type: Article

References (12)

1. Ettinger DS, Finkelstein DM, Abeloff MD et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer. A phase II study of the Eastern Cooperative Oncology Group. J Clin Oncol 1990, 8: 230-240.
2. Spiro SG, Souhami RL, Geddes DM. et al. Duration of chemotherapy in small cell lung cancer. A cancer research campaign trial. Br J Cancer 1989, 59: 578-583.
3. Roth BJ, Johsnon DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer. A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992, 10: 282-291.
4. Armitage P, Berry G. Statistical methods in medical research. 2nd Ed. Blackwell Scientific Publications, London 1987, Chap. 14.
5. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment Geneva WHO Offset Publication 1979, No 48.
6. Cox DR. Regression models and life-tables. J R Stat Soc 1972; B 34: 187-220.
7. Medical Council Research Lung Cancer Working Party. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989; 59: 584-590.
8. Medical Research Council Lung Cancer Working Party. A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC) I: Survival and prognostic factors. Br J Cancer 1993; 68: 1150-1156.
9. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small cell lung cancer: long-term results of a randomized trial. J Clin Oncol 1993; 11: 1230-1240.
10. Slevin PM, Stead ML, Brown JM et al. A randomised trial of three versus six courses of etoposide, ifosfamide, mesna and vincristine in small cell lung cancer. For the Yorkshire Thoraxic Group Leeds, England. Lung Cancer 1997; 18 (Supp. I) #20 abstr.
11. Shepherd FA, Amdemichael E, Evans WK et al. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994; 42: 64-70.
12. Medical Research Council Lung Cancer Working Party. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer. A stopped multicenter trial. Lancet 1996; 348: 563-666.